Aripiprazole-Induced Improvement in Tardive Dyskinesia

Uzun O Cansever A Ozsahin A. A case of relapsed tardive dyskinesia due to clozapine dose reduction. Int Clin Psychopharmacol 2001;16:369–70.

Kane JM Carson WH Saha AR McQuade RD Ingenito GG Zimbroff DL , and others. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763–71.

Toru M Miura S Kudo Y. Clinical experiences of OPC-14597, a dopamine autoreceptor agonist in schizophrenic patients. Neuropsychopharmacology 1994;10:122S.

Marangell LB Yudofsky SC Silver JM . Psychopharmacology and electroconvulsive therapy. In: Hales RE Yudofsky SC Talbott JA , editors. The American Psychiatric Press textbook of psychiatry. 3rd ed. Washington (DC): American Psychiatric Press; 1999. p 1070.

Inoue A Miki S Seto M Kikuchi T Morita S Ueda H , and others. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 1997;321:105–11.

Freudenreich O Goff DC . Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002;106:323–30.